Rheumatic disease and COVID-19: epidemiology and outcomes.
Rheumatic disease and COVID-19: epidemiology and outcomes.
复制标题
风湿病和共同疾病19：流行病学和结果。
DOI：
10.1038/s41584-020-00562-2
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Machado PM
中科院分区：
文献类型：
--
作者：
Hyrich KL;Machado PM
自2019冠状病毒病疫情爆发以来，已识别出多项严重疾病的风险因素。风湿性疾病患者，尤其是接受DMARD治疗的患者，感染SARS-CoV-2或严重COVID-19疾病的风险是否增加仍不清楚，尽管流行病学研究提供了一些见解。当将类风湿性关节炎、系统性红斑狼疮或银屑病患者作为一个综合组进行分析时，与未患这些疾病的患者相比，其死于COVID-19的风险可能略有增加，尽管疾病活动和治疗在这一风险估计中的作用未被考虑在内。用细胞因子抑制剂治疗可以降低SARS-SoV-2感染的风险（通过SARS-CoV-2抗体的产生来衡量），尽管这种保护作用的机制尚不清楚。长期使用中等或高剂量的糖皮质激素（≥10 mg/天泼尼松龙或等效药物）与因重度COVID-19住院相关。
Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have been identified. Whether patients with rheumatic diseases, especially those receiving DMARDs, are at an increased risk of SARS-CoV-2 infection or severe COVID-19 disease remains unclear, although epidemiological studies are providing some insight. Patients with rheumatoid arthritis, systemic lupus erythematosus or psoriasis, when analysed as a combined group, might have a slightly increased risk of death from COVID-19 compared to those without these diseases, although the role of disease activity and treatment in this risk estimation was not taken into account. Treatment with cytokine inhibitors could reduce the risk of SARS-SoV-2 infection (as measured by development of SARS-CoV-2 antibodies), although the mechanisms of this protective effect are not clear. Chronic use of glucocorticoids at moderate or high doses (≥10 mg per day prednisolone or equivalent) is associated with hospitalization for severe COVID-19.
登录
查看更多内容
影响因子：
16.6
作者：
Simon, David;Tascilar, Koray;Schett, Georg
通讯作者：
Schett, Georg
影响因子：
5
作者：
Zhang, Bicheng;Zhou, Xiaoyang;Wang, Jun
通讯作者：
Wang, Jun
DOI：
10.1016/s2213-2600(20)30404-5
发表时间：
2020-12
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Leisman DE;Ronner L;Pinotti R;Taylor MD;Sinha P;Calfee CS;Hirayama AV;Mastroiani F;Turtle CJ;Harhay MO;Legrand M;Deutschman CS
通讯作者：
Deutschman CS
影响因子：
64.8
作者：
Williamson EJ;Walker AJ;Bhaskaran K;Bacon S;Bates C;Morton CE;Curtis HJ;Mehrkar A;Evans D;Inglesby P;Cockburn J;McDonald HI;MacKenna B;Tomlinson L;Douglas IJ;Rentsch CT;Mathur R;Wong AYS;Grieve R;Harrison D;Forbes H;Schultze A;Croker R;Parry J;Hester F;Harper S;Perera R;Evans SJW;Smeeth L;Goldacre B
通讯作者：
Goldacre B
影响因子：
27.4
作者：
Gianfrancesco, Milena;Hyrich, Kimme L.;Robinson, Philip C.
通讯作者：
Robinson, Philip C.